THE ACTIVITY OF 2-SUBSTITUTED QUINOLINE ALKALOIDS IN BALB/C MICE INFECTED WITH LEISHMANIA-DONOVANI

被引:48
作者
FOURNET, A
GANTIER, JC
GAUTHERET, A
LEYSALLES, L
MUNOS, MH
MAYRARGUE, J
MOSKOWITZ, H
CAVE, A
HOCQUEMILLER, R
机构
[1] FAC PHARM CHATENAY MALABRY, CNRS, PHARMACOGNOISE LAB, F-92296 CHATENAY MALABRY MALABRY, FRANCE
[2] FAC PHARM CHATENAY MALABRY, CNRS, CHIM ORGAN LAB, F-92296 CHATENAY MALABRY, FRANCE
[3] UNIV PARIS 11, FAC PHARM, BIOL & CONTROLE ORGAN PARASITES LAB, F-92296 CHATENAY MALABRY, FRANCE
关键词
D O I
10.1093/jac/33.3.537
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Potent antileishmanial activity has recently been described in vivo when certain 2-substituted quinoline alkaloids are administered to mice with cutaneous leishmaniasis. We now report the antileishmanial activity of four 2-substituted quinoline alkaloids, namely chimanine D or 2-(1′,2′-trans-epoxypropyl) quinoline (I), 2-n-propylquinoline (II), 2-styrylquinoline (III) and 2-(2′-hydroxypropyl) quinoline (IV), for experimental treatment of visceral leishmaniasis in infected BALB/c mice. Subcutaneous treatment with chimanine D for 10 days at 0·54 mmol/kg per day resulted in 86·6% parasite suppression in the liver. Oral administration of 0·54 mmol/kg of 2-n-propylquinoline once daily for 5 or 10 days to L. donovani-infected mice suppressed parasite burdens in liver by 87·8 and 99·9%, respectively. Cutaneous administration of meglumine antimonate for 10 days resulted in 97·4% parasite suppression in the liver. This study is, to our knowledge, the first to demonstrate the activity of 2-substituted quinoline alkaloids in experimental treatment of visceral leishmaniasis. Further biological and chemical studies of these products might yet prove helpful for the development of new antileishmanial drugs. © 1994 The British Society for Antimicrobial Chemotherapy.
引用
收藏
页码:537 / 544
页数:8
相关论文
共 20 条
  • [1] SUPPRESSION OF LEISHMANIA-DONOVANI BY ORAL-ADMINISTRATION OF A BIS(BENZYL)POLYAMINE ANALOG
    BAUMANN, RJ
    MCCANN, PP
    BITONTI, AJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (07) : 1403 - 1407
  • [2] BERMAN JD, 1988, REV INFECT DIS, V10, P560
  • [3] LEISHMANIA-DONOVAN - ORAL EFFICACY AND TOXICITY OF FORMYCIN-B IN THE INFECTED HAMSTER
    BERMAN, JD
    KEENAN, CM
    LAMB, SR
    HANSON, WL
    WAITS, VB
    [J]. EXPERIMENTAL PARASITOLOGY, 1983, 56 (02) : 215 - 221
  • [4] VISCERAL LEISHMANIASIS UNRESPONSIVE TO ANTIMONIAL DRUGS .3. SUCCESSFUL TREATMENT USING A COMBINATION OF SODIUM STIBOGLUCONATE PLUS ALLOPURINOL
    CHUNGE, CN
    GACHIHI, G
    MUIGAI, R
    WASUNNA, K
    RASHID, JR
    CHULAY, JD
    ANABWANI, G
    OSTER, CN
    BRYCESON, ADM
    [J]. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1985, 79 (05) : 715 - 718
  • [5] LIPOSOMAL AMPHOTERICIN-B IN THE TREATMENT OF VISCERAL LEISHMANIASIS
    CROFT, SL
    DAVIDSON, RN
    THORNTON, EA
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 28 : 111 - 118
  • [6] THE ACTIVITY OF ALKYL PHOSPHORYLCHOLINES AND RELATED DERIVATIVES AGAINST LEISHMANIA-DONOVANI
    CROFT, SL
    NEAL, RA
    PENDERGAST, W
    CHAN, JH
    [J]. BIOCHEMICAL PHARMACOLOGY, 1987, 36 (16) : 2633 - 2636
  • [7] THE ACTIVITY OF HYDROXYNAPHTHOQUINONES AGAINST LEISHMANIA-DONOVANI
    CROFT, SL
    HOGG, J
    GUTTERIDGE, WE
    HUDSON, AT
    RANDALL, AW
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 30 (06) : 827 - 832
  • [8] RECENT DEVELOPMENTS IN THE CHEMOTHERAPY OF LEISHMANIASIS
    CROFT, SL
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1988, 9 (10) : 376 - 381
  • [9] FOURNET A, 1991, Patent No. 12174
  • [10] FOURNET A, 1992, Patent No. 903